Choosing Appropriate Estimands in Clinical Trials (Leuchs et al)

Abstract

Get full access to this article

View all access options for this article.

References

Leuchs

Zinserling

Brandt

Wirtz

Benda

. Choosing appropriate estimands in clinical trials [published online February 17, 2015]. Therapeutic Innovation & Regulatory Science. doi:10.1177/2168479014567317.

O’Kelly

Berry

Walp

Garrett

. Lifecycle modeling and simulation: current practice and future impact on healthcare innovation and delivery. Therapeutic Innovation & Regulatory Science. 2013;47(2):175–182.

International Conference on Harmonisation. ICH harmonised tripartite guideline: general considerations for clinical trials: E8. 1997. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf. Accessed March 2015.

Fritsch

. Multiplicity issues in FDA-reviewed clinical trials. Presented at: EMA Workshop on Multiplicity Issues in Clinical Trials; November 16, 2012; London, UK. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500140627.pdf. Accessed March 2015.